Upadacitinib in Crohn’s disease

References

• Farrag K, Ulrich-Rückert S, Schulz F, et al. Chronisch-entzündliche Darmerkrankungen: Status quo und was die Zukunft bringen kann. Deutsches Ärzteblatt. 2023;120:27–28.
   Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–342. doi: 10.1038/nri3661
   PubMed Web of Science ®Google Scholar
• Casalegno Garduño R, Däbritz J. New insights on CD8+ T cells in inflammatory bowel disease and therapeutic approaches. Front Immunol. 2021;12:738762. doi: 10.3389/fimmu.2021.738762
   PubMed Web of Science ®Google Scholar
• Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 pathway in Crohn’s disease. Front Immunol. 2021;12:622934. doi: 10.3389/fimmu.2021.622934
   PubMed Web of Science ®Google Scholar
• Parigi TL, D’Amico F, Danese S. Upadacitinib for Crohn’s disease and ulcerative colitis treatment: hitting the selective JAKpot. Gastroenterology. 2021;160(5):1472–1474. doi: 10.1053/j.gastro.2020.04.034
   PubMed Web of Science ®Google Scholar
• Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5(1):2–3. doi: 10.1016/S2468-1253(19)30358-9
   PubMed Web of Science ®Google Scholar
• Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22. doi: 10.1038/s41572-020-0156-2
   PubMed Web of Science ®Google Scholar
• Burisch J, Weimers P, Pedersen N, et al. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease–an ECCO-EpiCom study. J Crohn’s Colitis. 2014;8(9):1030–1042. doi: 10.1016/j.crohns.2014.01.028
   Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD-Lessons from real-world experience; a systematic review and pooled analysis. J Crohn’s Colitis. 2018;12(2):245–257. doi: 10.1093/ecco-jcc/jjx143
   Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–698. doi: 10.1038/ajg.2011.103
   PubMed Web of Science ®Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Fachinformation: Humira® 40 mg/0,4 ml Injektionslösung in einer Fertigspritze.
   Google Scholar
• Janssen Biologics BV. Remicade® 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung.
   Google Scholar
• Takeda Pharma A/S. Entyvio® 300 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung.
   Google Scholar
• Takeda Pharma A/S. Entyvio® 108 mg Injektionslösung.
   Google Scholar
• Janssen-Cilag International NV. Stelara® 45 mg/90 mg Injektionslösung in einer Fertigspritze.
   Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Skyrizi® 150 mg Injektionslösung im Fertigpen und in einer Fertigspritze (Risankizumab).
   Google Scholar
• Wilkens R, Novak KL, Maaser C, et al. Relevance of monitoring transmural disease activity in patients with Crohn’s disease: current status and future perspectives. Therap Adv Gastroenterol. 2021;14:17562848211006672. doi: 10.1177/17562848211006672
   Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–422. doi: 10.1053/j.gastro.2007.05.051
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2019;13(2):144–164. doi: 10.1093/ecco-jcc/jjy113
   Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative Colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. doi: 10.14309/ajg.0000000000000152
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel J-F, Sands BE, et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43(3):317–333. doi: 10.1111/apt.13475
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1 year prevents progression of early Crohn’s disease. Gastroenterology. 2020;159(1):139–147. doi: 10.1053/j.gastro.2020.03.039
   PubMed Web of Science ®Google Scholar
• Yzet C, Diouf M, le Mouel J-P, et al. Complete endoscopic healing associated with better outcomes than partial endoscopic healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2020;18(10):2256–2261. doi: 10.1016/j.cgh.2019.11.025
   PubMed Web of Science ®Google Scholar
• Klenske E, Bojarski C, Waldner M, et al. Targeting mucosal healing in Crohn’s disease: what the clinician needs to know. Therap Adv Gastroenterol. 2019;12:1756284819856865. doi: 10.1177/1756284819856865
   Web of Science ®Google Scholar
• Baert F, Moortgat L, van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8; quiz e10–1. doi: 10.1053/j.gastro.2009.09.056
   Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–1780. doi: 10.1038/ajg.2014.242
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395. doi: 10.1056/NEJMoa0904492
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351–361.e5. doi: 10.1053/j.gastro.2016.09.046
   PubMed Web of Science ®Google Scholar
• Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn’s disease management. United European Gastroenterol J. 2020;8(2):133–139. doi: 10.1177/2050640619887316
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi: 10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Steroid-dependent Crohn’s disease. Can J Gastroenterol. 2000;14 Suppl C(suppl c):17C–22C. doi: 10.1155/2000/513130
   PubMedGoogle Scholar
• Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2011;34(3):306–317. doi: 10.1111/j.1365-2036.2011.04717.x
   PubMed Web of Science ®Google Scholar
• Dignass A, van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s & Colitis. 2010;4(1):28–62. doi: 10.1016/j.crohns.2009.12.002
   PubMed Web of Science ®Google Scholar
• Sturm A, Atreya R, Bettenworth D, et al. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol. 2022;60(3):332–418. doi: 10.1055/a-1713-3941
   PubMedGoogle Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s & Colitis. 2017;11(1):3–25. doi: 10.1093/ecco-jcc/jjw168
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohn’s & Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180
   PubMed Web of Science ®Google Scholar
• Dignass A, Rath S, Kleindienst T, et al. Review article: translating STRIDE-II into clinical reality - opportunities and challenges. Aliment Pharmacol Ther. 2023;58(5):492–502. doi: 10.1111/apt.17622
   PubMed Web of Science ®Google Scholar
• Hazel K, O’Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297. doi: 10.1177/2040622319899297
   Web of Science ®Google Scholar
• Hemperly A, Sandborn WJ, Vande Casteele N. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(12):2527–2542. doi: 10.1093/ibd/izy189
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10:212. doi: 10.3389/fphar.2019.00212
   PubMed Web of Science ®Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Zusammenfassung der Merkmale des Arzneimittels (SmPC): RINVOQ® (Upadacitinib).
   Google Scholar
• Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–1980. doi: 10.1056/NEJMoa2212728
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66(1):311–328. doi: 10.1146/annurev-med-051113-024537
   PubMedGoogle Scholar
• Montilla AM, Gómez-García F, Gómez-Arias PJ, et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and Alopecia Areata. Dermatol Ther (Heidelb). 2019;9(4):655–683. doi: 10.1007/s13555-019-00329-y
   PubMed Web of Science ®Google Scholar
• Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30(2):88–106. doi: 10.3109/08977194.2012.660936
   PubMed Web of Science ®Google Scholar
• Sideris N, Vakirlis E, Tsentemeidou A, et al. Under development JAK inhibitors for dermatologic diseases. Mediterr J Rheumatol. 2020;31(Suppl 1):137–144. doi: 10.31138/mjr.31.1.137
   PubMedGoogle Scholar
• Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–662. doi: 10.1038/nrm909
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900–911. doi: 10.1038/nri1226
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez J-B. Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi: 10.1021/jm401490p
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. doi: 10.1038/nrrheum.2015.167
   PubMed Web of Science ®Google Scholar
• Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059–20063. doi: 10.1074/jbc.R700016200
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287. doi: 10.1111/j.1600-065X.2008.00754.x
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi: 10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Gao Q, Liang X, Shaikh AS, et al. JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases. Curr Drug Targets. 2018;19(5):487–500. doi: 10.2174/1389450117666161207163054
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet (London, England). 2012;380(9853):1590–1605. doi: 10.1016/S0140-6736(12)60026-9
   PubMed Web of Science ®Google Scholar
• Rosa Degasperi G. Mucosal immunology in the inflammatory bowel diseases. In: Franco Leal R Torriani T, editors Biological therapy for inflammatory bowel disease. IntechOpen; 2020.
   Google Scholar
• Belkaid Y, Harrison OJ. Homeostatic immunity and the microbiota. Immunity. 2017;46(4):562–576. doi: 10.1016/j.immuni.2017.04.008
   PubMed Web of Science ®Google Scholar
• Ben Ghezala I, Charkaoui M, Michiels C, et al. Small molecule drugs in inflammatory bowel diseases. Pharmaceuticals. 2021;14(7):637. doi: 10.3390/ph14070637
   Web of Science ®Google Scholar
• Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1–8. doi: 10.1016/j.phrs.2013.06.007
   PubMed Web of Science ®Google Scholar
• Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology. 2021;60(Supple 2):ii45–ii51. doi: 10.1093/rheumatology/keaa896
   PubMedGoogle Scholar
• O’shea JJ. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheumatic Dis. 2004;63 Suppl 2(Suppl 2):ii67–ii71. doi: 10.1136/ard.2004.028290
   PubMedGoogle Scholar
• Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–337. doi: 10.1038/s41575-020-0273-0
   PubMed Web of Science ®Google Scholar
• Wang L, Hu Y, Song B, et al. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease. Inflam Res Official J European Histamine Res Soc et al. 2021;70(7):753–764. doi: 10.1007/s00011-021-01482-x
   Google Scholar
• Cordes F, Foell D, Ding JN, et al. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease. World J Gastroenterol. 2020;26(28):4055–4075. doi: 10.3748/wjg.v26.i28.4055
   PubMed Web of Science ®Google Scholar
• Mahapatro M, Erkert L, Becker C. Cytokine-mediated crosstalk between immune cells and epithelial cells in the gut. Cells. 2021;10(1):111. doi: 10.3390/cells10010111
   PubMed Web of Science ®Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Dossier zur Nutzenbewertung gemäß § 35a SGB V. Upadacitinib (RINVOQ). Modul 2 - Stand 24.04.2023.
   Google Scholar
• Flamant M, Rigaill J, Paul S, et al. Advances in the development of janus kinase inhibitors in inflammatory bowel disease: future prospects. Drugs. 2017;77(10):1057–1068. doi: 10.1007/s40265-017-0755-8
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28(1):445–489. doi: 10.1146/annurev-immunol-030409-101212
   PubMed Web of Science ®Google Scholar
• Eken A, Oukka M. Interleukin 23 in IBD pathogenesis. 2016.
   Google Scholar
• Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, et al. Crohn’s disease and ulcerative colitis show unique cytokine profiles. Cureus. 2017;9(4):e1177. doi: 10.7759/cureus.1177
   PubMed Web of Science ®Google Scholar
• Mortha A, Burrows K. Cytokine networks between innate lymphoid cells and myeloid cells. Front Immunol. 2018;9:191. doi: 10.3389/fimmu.2018.00191
   PubMed Web of Science ®Google Scholar
• Galien R. Janus kinases in inflammatory bowel disease: four kinases for multiple purposes. Pharmacol Rep. 2016;68(4):789–796. doi: 10.1016/j.pharep.2016.04.001
   PubMed Web of Science ®Google Scholar
• Wang A, Singh K, Ibrahim W, et al. The promise of JAK inhibitors for treatment of Sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med. 2020;93(1):187–195.
   PubMed Web of Science ®Google Scholar
• Soendergaard C, Bergenheim FH, Bjerrum JT, et al. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018;192:100–111. doi: 10.1016/j.pharmthera.2018.07.003
   PubMed Web of Science ®Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Fachinformation für RINVOQ® 15 mg Retardtabletten, RINVOQ® 30 mg Retardtabletten, RINVOQ® 45 mg Retardtabletten.
   Google Scholar
• Friedman M, Frank KE, Aguirre A, et al. Structure activity optimization of 6H-pyrrolo2,3-e1,2,4triazolo4,3-apyrazines as Jak1 kinase inhibitors. Bioorganic Med Chem Lett. 2015;25(20):4399–4404. doi: 10.1016/j.bmcl.2015.09.020
   PubMedGoogle Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). Bmc Rheumatology. 2018;2(1):23. doi: 10.1186/s41927-018-0031-x
   PubMedGoogle Scholar
• Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol. 2009;387(1):219–232. doi: 10.1016/j.jmb.2009.01.041
   PubMed Web of Science ®Google Scholar
• Ernest-Suarez K, Panaccione R. Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis. Therap Adv Gastroenterol. 2023;16:17562848231158235. doi: 10.1177/17562848231158235
   Web of Science ®Google Scholar
• Mohamed M-E, Trueman S, Othman AA, et al. Development of in vitro-in vivo correlation for upadacitinib extended-release tablet formulation. AAPS J. 2019;21(6):108. doi: 10.1208/s12248-019-0378-y
   PubMed Web of Science ®Google Scholar
• Mohamed M-E, Zeng J, Marroum PJ, et al. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clinical Pharm In Drug Dev. 2019;8(2):208–216. doi: 10.1002/cpdd.462
   PubMed Web of Science ®Google Scholar
• Mohamed M-E, Klünder B, Othman AA. Clinical pharmacokinetics of Upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59(5):531–544. doi: 10.1007/s40262-019-00855-0
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123–2138.e8. doi: 10.1053/j.gastro.2020.01.047
   PubMed Web of Science ®Google Scholar
• Colombel JF, Hisamatsu T, Bresso F, et al. DOP38 upadacitinib therapy reduces Crohn’s disease symptoms within the first week of induction therapy. J Crohn’s & Colitis. 2023;17(Supplement_1):i102–i103. doi: 10.1093/ecco-jcc/jjac190.0078
   Google Scholar
• Dubinsky MC, D’Haens G, Dewit O, et al. DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib. J Crohn’s & Colitis. 2023;17(Supplement_1):i104–i106. doi: 10.1093/ecco-jcc/jjac190.0080
   Google Scholar
• DaHaens G, Seidelin JB, Lügering A. Delayed clinical response in patients with Crohn’s disease receiving upadacitinib therapy. DDW ePoster(Tu1705). 2023;164(6):S-1085–S–1086. doi: 10.1016/S0016-5085(23)03521-7
   Google Scholar
• Panés J, Louis E, Bossuyt P, et al. P439 induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease. J Crohn’s & Colitis. 2023;17(Supplement_1):i568–i569. doi: 10.1093/ecco-jcc/jjac190.0569
   Google Scholar
• Panés J, Louis E, Bossuyt P, et al. P786 induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease. J Crohn’s & Colitis. 2023;17(Supplement_1):i919–i920. doi: 10.1093/ecco-jcc/jjac190.0916
   PubMedGoogle Scholar
• Schreiber SW, Lim A, Lacerda AP, et al. P630 upadacitinib improves clinical outcomes in patients with moderate to severely active Crohn’s disease irrespective of previous failure to respond to Biologics or conventional therapies. J Crohn’s & Colitis. 2023;17(Supplement_1):i759–i762. doi: 10.1093/ecco-jcc/jjac190.0760
   Google Scholar
• Feagan BG, Horst S, Dryden G, et al. OP17 upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn’s disease irrespective of previous failure to respond to Biologics or conventional therapies. J Crohn’s & Colitis. 2023;17(Supplement_1):i22–i25. doi: 10.1093/ecco-jcc/jjac190.0017
   Google Scholar
• Peyrin-Biroulet L, Parkes G, Rodríguez C, et al. OP16 endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics. J Crohn’s & Colitis. 2023;17(Supplement_1):i20–i22. doi: 10.1093/ecco-jcc/jjac190.0016
   Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet (London, England). 2022;399(10341):2113–2128. doi: 10.1016/S0140-6736(22)00581-5
   PubMed Web of Science ®Google Scholar
• Panaccione R, Panés J, Peyrin-Biroulet L, et al. S1193 safety of upadacitinib in IBD: pooled analysis of phase 3 maintenance studies, U-ACHIEVE and U-ENDURE, in patients with moderately to severely active ulcerative colitis or Crohn’s disease. Am J Gastroenterol. 2023;118(10S):S909–S910. doi: 10.14309/01.ajg.0000954412.44947.f2
   Google Scholar
• European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. Available from: https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf-0.
   Google Scholar
• U.S. Food & Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Approved uses also being limited to certain patients. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death#:~:text=FDA%20is%20requiring%20new%20and,treat%20certain%20serious%20inflammatory%20conditions.
   Google Scholar
• Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307–320. doi: 10.1016/S2468-1253(22)00427-7
   PubMed Web of Science ®Google Scholar
• Raine T, Danese S. Breaking through the therapeutic ceiling: what will it take? Gastroenterology. 2022;162(5):1507–1511. doi: 10.1053/j.gastro.2021.09.078
   PubMed Web of Science ®Google Scholar